Request Demo
Last update 20 Jun 2026
AZD-8965
Last update 20 Jun 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms AZD-8965 |
Target |
Action inhibitors |
Mechanism ARG1 inhibitors(Arginase-1 inhibitors), ARG2 inhibitors(arginase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Related
2
Clinical Trials associated with AZD-8965NCT07652658
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)
NCT06502379
A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD8965 Following Single and Multiple Ascending Dose Administration to Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
100 Clinical Results associated with AZD-8965
Login to view more data
100 Translational Medicine associated with AZD-8965
Login to view more data
100 Patents (Medical) associated with AZD-8965
Login to view more data
100 Deals associated with AZD-8965
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | Phase 2 | United States | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | China | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | Japan | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | Argentina | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | Australia | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | Bulgaria | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | Canada | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | Chile | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | Denmark | 15 Jun 2026 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | France | 15 Jun 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free